Core Insights - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [1][4] - The company will present key findings at the 2025 American Association for Cancer Research Meeting, including studies on CM24 for pancreatic cancer and NT219 for colorectal and head and neck cancers [1][2][3][4] Company Overview - Purple Biotech's oncology pipeline includes CM24, NT219, and CAPTN-3, with CM24 being a humanized monoclonal antibody targeting CEACAM1, which is involved in tumor immune evasion [4] - The company has completed a Phase 2 study for CM24 in combination with nivolumab and chemotherapy, showing significant improvements across all efficacy endpoints and identifying two potential serum biomarkers [4] - NT219 is a dual inhibitor targeting IRS1/2 and STAT3, demonstrating anti-tumor activity in combination with cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4] - CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies designed to enhance localized immune responses within the tumor microenvironment [4] Upcoming Presentations - The final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy will be presented on April 30, 2025 [2] - A study on APC-loss as a potential biomarker for NT219 treatment in colorectal cancer will be presented on April 27, 2025 [3] - Research on NT219's ability to overcome immune evasion mechanisms in head and neck squamous cell carcinoma will be presented on April 28, 2025 [3]
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting